Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Molecules for early diagnosis and treatment of cancer

A technology of laryngeal squamous cell carcinoma and reagent, applied in the field of biomedicine, can solve the problems of difficulty in early diagnosis of laryngeal cancer and high postoperative recurrence rate

Active Publication Date: 2020-10-02
BEIJING MEDINTELL BIOMED CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The reasons are mainly manifested in three aspects: First, the early clinical manifestations of laryngeal cancer are diverse, which brings great difficulty to the early diagnosis of laryngeal cancer. Most patients fail to receive timely and effective treatment in the early stage. Molecular markers are the key to improving the early diagnosis rate of laryngeal cancer
Second, the treatment of laryngeal cancer is mainly based on surgery, supplemented by radiotherapy and chemotherapy. Although partial laryngectomy and the early stage of glottic laryngeal cancer are treated with C02 laser treatment, the laryngeal function is completely or partially preserved, and postoperative complications Therefore, the quality of life of patients is improved, but the postoperative recurrence rate is still high. If the tumor-promoting genes or tumor suppressor factors of laryngeal cancer can be found out, and potential drug targets can be screened out, it will be a great opportunity for the development of laryngeal cancer. Cancer-related specific vaccines or / and new anti-cancer drugs lay the foundation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Molecules for early diagnosis and treatment of cancer
  • Molecules for early diagnosis and treatment of cancer
  • Molecules for early diagnosis and treatment of cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0048] Example 1 Molecular verification of differential expression

[0049] 1. Research object

[0050] The cancer tissues and corresponding paracancerous tissues of 45 patients with laryngeal squamous cell carcinoma were collected. Inclusion and exclusion criteria: ①Patients have no primary tumor other than the primary tumor, and the primary tumor has not metastasized; ②No history of cardiovascular and cerebrovascular diseases such as diabetes and hypertension; ③No infectious diseases such as hepatitis, syphilis, tuberculosis, and HIV Medical history; ④ no family history of genetic diseases; ⑤ no radiotherapy, chemotherapy and biological therapy before operation.

[0051] Sampling precautions: When cutting tumor specimens, pay attention to cutting non-necrotic tumor tissue in the central area of ​​the tumor. When cutting normal adjacent tissues, try to stay away from the tumor as far as possible, and be more than 1.5cm away from the edge of the tumor. Try to cut mucosal epit...

Embodiment 2

[0103] Example 2 LncRNA silencing

[0104] 1. Cell culture

[0105] The human laryngeal squamous carcinoma cell line Hep2 was incubated in RPMI1640 medium containing 10% fetal bovine serum and 1% P / S at 37°C and 5% CO 2 , cultured in an incubator with a relative humidity of 90%. The medium was changed once every 2-3 days, and the cells grew well and showed a monolayer adherent growth. Use 0.25% EDTA-containing trypsin for routine digestion and passaging.

[0106] 2. Transfection

[0107] 1) Treatment of cells before transfection

[0108] The day before transfection, 3~5×10 5 Cells / well were cultured in antibiotic-free medium for one day, and the cell density was 30-50% at the time of transfection, and replaced with serum-free medium before transfection.

[0109] 2) Design of siRNA

[0110] Two groups were set up in the experiment: negative control group (siNC, transfected with negative control siRNA), and siLncRNA silencing group (transfected with siRNA against LncRNA)....

Embodiment 3

[0131] Example 3 The effect of LncRNA expression on the proliferation of laryngeal squamous cell carcinoma cells

[0132] WST-1 method was used to detect the effect of lncRNA expression on the proliferation of laryngeal squamous cell carcinoma cells.

[0133] The next day after cell transfection, adjust the cell density to 1×10 2 / μl, seeded in a 96-well plate (100 μl / well), and each group set up three replicate wells. 37°C, 5% CO 2 After culturing for 72 hours, add 10 μl of WST-1 and incubate for 2 hours, then detect the optical density (D) value of the cells at a wavelength of 450 nm with a microplate reader.

[0134] The result is as figure 1 As shown, the difference between the groups was statistically significant (* P P <0.05). It shows that the expression of LOC730101, LOC442028, LOC100507437 and LOC158435 can inhibit the proliferation of laryngeal squamous cell carcinoma cells.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses molecules for early diagnosis and treatment of cancer. The molecules are LOC442028. The invention also discloses a reagent and reagent kit for detecting the molecules. Throughresearch, the inventor finds that the molecules can also become a medicine target for treating laryngeal squamous cell carcinoma. The research findings provide a theoretical basis for clinical diagnosis of the laryngeal squamous cell carcinoma and treatment of the laryngeal squamous cell carcinoma.

Description

technical field [0001] The invention belongs to the field of biomedicine and relates to molecules used for early diagnosis and treatment of cancer. Background technique [0002] Laryngeal cancer is a common malignant tumor in the head and neck, accounting for the second place in the head and neck tumors. Its incidence rate accounts for about 5% of all malignant tumors in the whole body. Most squamous cell carcinomas originate in the vocal cords, accounting for about 60%. Huang Xinhui et al conducted a retrospective analysis on 306 cases of laryngeal malignant tumors and found that squamous cell carcinoma accounted for 99.7% of all malignant tumors, among which squamous cell carcinoma with high and moderate differentiation was the main type; the primary site of laryngeal cancer was glottic type The majority, followed by supraglottic type, subglottic type; smoking, drinking are closely related to the occurrence of tumors. Although surgery, radiotherapy, and chemotherapy can ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6886C12N15/11A61K31/713A61K45/00A61P35/00
CPCA61K31/713A61K45/00A61P35/00C12Q1/6886C12Q2600/118C12Q2600/136C12Q2600/158C12Q2600/178
Inventor 杨承刚孙耀兰
Owner BEIJING MEDINTELL BIOMED CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com